Glofitamab Plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): results from a Phase Ib study
Blood（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要